Fiche publication
Date publication
décembre 2016
Journal
Expert opinion on drug metabolism & toxicology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BARDOU Marc
,
Pr BONNIAUD Philippe
Tous les auteurs :
Luu M, Bardou M, Bonniaud P, Goirand F
Lien Pubmed
Résumé
Omalizumab is a subcutaneously administrated monoclonal anti-IgE antibody indicated in adults, adolescents and children 6 years of age and older with moderate to severe allergic asthma uncontrolled by conventional pharmacological treatments and sensitization to at least one perennial allergen. Area covered: This drug evaluation summarizes published data on pharmacokinetic and pharmacodynamic properties of omalizumab, on clinical efficacy and safety, including real-world evidence, and provides a medico-economic evaluation of the drug. Expert opinion: Omalizumab represents an efficient therapeutic option for the management of patients with uncontrolled moderate/severe allergic asthma. It provides a significant reduction in the asthma exacerbation rate with a steroid-sparing effect, an improvement in quality of life in adults and adolescents, despite a lack of evidence about its efficacy specifically in severe allergic asthma. Clinical trials have demonstrated its efficacy in the pediatric population but further real-life evidence is expected to better characterize long-term effects in this population. There is still some debate about the optimal treatment duration but, to date, it is recommended not to stop the treatment as cessation has resulted in symptom recurrence. Omalizumab is an expensive treatment, but a key therapeutic option when used for uncontrolled severe allergic asthma.
Mots clés
Adolescent, Adult, Allergens, immunology, Anti-Asthmatic Agents, administration & dosage, Asthma, drug therapy, Child, Humans, Immunoglobulin E, immunology, Injections, Subcutaneous, Omalizumab, administration & dosage, Quality of Life, Time Factors
Référence
Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1503-1511
